Drug Information

Drug General Information
Drug ID
D0P2GU
Former ID
DIB008050
Drug Name
CSL-362-AML
Drug Type
Antibody
Indication Leukemia [ICD9: 208.9; ICD10:C90-C95] Phase 1 [549073]
Company
Janssen Biotech
Target and Pathway
Target(s) Interleukin 3 receptor Target Info [532602]
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Apoptosis
Jak-STAT signaling pathway
Hematopoietic cell lineage
NetPath Pathway IL5 Signaling Pathway
IL3 Signaling Pathway
Pathway Interaction Database IL3-mediated signaling events
Reactome GPVI-mediated activation cascade
G beta:gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways IL-3 Signaling Pathway
Interleukin-2 signaling
Interleukin-3, 5 and GM-CSF signaling
References
Ref 549073Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031973)
Ref 532602Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.